

Form PTO-1449 (modified)

Atty. Docket No.  
UVMO:024USSerial No.  
10/808,248

List of Patents and Publications for Applicant's

Applicant

Elmer M. Price *et al.*

## INFORMATION DISCLOSURE STATEMENT

Filing Date:  
March 24, 2004Group:  
1614

U.S. Patent Documents

Foreign Patent Documents

Other Art

See Page 1

See Page 1

See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
WJ	C1	Alexander <i>et al.</i> , "Gene transfer of endothelial nitric oxide synthase but not Cu/Zn superoxide dismutase restores nitric oxide availability in the SHRSP," <i>Cardiovascular Res.</i> , 47:609-617, 2000.
	C2	Bachmair <i>et al.</i> , "The degradation signal in a short-lived protein," <i>Cell</i> , 56:1019-1032, 1989.
	C3	Bivalacqua <i>et al.</i> , "Adenoviral gene transfer of endothelial nitric oxide synthase (eNOS) to the penis improves age-related erectile dysfunction in the rat," <i>Intl. J. Impotence Res.</i> , 12 Suppl 3:S8-17, 2000.
	C4	Cable <i>et al.</i> , "Expression and function of a recombinant endothelial nitric oxide synthase gene in porcine coronary arteries," <i>Cardiovascular Res.</i> , 35(3):553-559, 1997.
	C5	Cable <i>et al.</i> , "Recombinant endothelial nitric oxide synthase-transduced human saphenous veins: gene therapy to augment nitric oxide production in bypass conduits," <i>Circulation</i> , 96(9 Suppl.):II173-178, 1997.
	C6	Calles- Escandon and Cipolla, "Diabetes and endothelial dysfunction: a clinical perspective," <i>Endocrine Reviews</i> , 22:36-52, 2001.
	C7	Darbinian <i>et al.</i> , "Growth inhibition of glioblastoma cells by human Pur(alpha)," <i>J. Cell. Physiol.</i> , 189:334-340, 2001.
MM	C8	De Vries <i>et al.</i> , "Endothelial dysfunction in diabetes," <i>British J. Pharmacol.</i> , 130:963-974, 2000.

25413943.1

EXAMINER:

*D. Meek*

DATE CONSIDERED:

*3/29/01*


EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UVMO:024US	Serial No. 10/808,248
List of Patents and Publications for Applicant's		Applicant Elmer M. Price <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Filing Date: March 24, 2004	Group: 1614
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C9	Ferrario <i>et al.</i> , "The hypertension-lipid connection: insights into the relation between angiotensin II and cholesterol in atherogenesis," <i>Amer. J. Med. Sciences</i> , 323:17-24, 2002.
	C10	Forstermann <i>et al.</i> , "Isoforms of nitric-oxide synthase: purification and regulation," <i>Methods Enzymology</i> , 233:258-265, 1994.
	C11	Frankel and Pabo, "Cellular uptake of the tat protein from human immunodeficiency virus," <i>Cell</i> , 55:1189-1193, 1988.
	C12	Frankel <i>et al.</i> , "Dimerization of the tat protein from human immunodeficiency virus: a cysteine-rich peptide mimics the normal metal-linked dimer interface," <i>Proc. Natl. Acad. Sci., USA</i> , 85(17):6297-6300, 1988.
	C13	Frankel <i>et al.</i> , "Tat protein from human immunodeficiency virus forms a metal-linked dimer," <i>Science</i> , 240:70-73, 1988.
	C14	Garcia <i>et al.</i> , "Functional domains required for tat-induced transcriptional activation of the HIV-1 long terminal repeat," <i>EMBO J.</i> , 7(10):3143-3147, 1988.
	C15	Guerci <i>et al.</i> , "Endothelial dysfunction and type 2 diabetes. Part 1: physiology and methods for exploring the endothelial function," <i>Diabetes Metab.</i> , 27(4pt1):425-434, 2001.
	C16	Guerci <i>et al.</i> , "Endothelial dysfunction and type 2 diabetes. Part 2: altered endothelial function and the effects of treatments in type 2 diabetes mellitus," <i>Diabetes Metab.</i> , 27:436-447, 2001.
	C17	Han <i>et al.</i> , "Efficient intracellular delivery of GFP by homeodomains of Drosophila Fushi-tarazu and Engrailed proteins," <i>Molecules and Cells</i> , 10:728-732, 2000.
	C18	Hauber <i>et al.</i> , "Mutational analysis of the conserved basic domain of human immunodeficiency virus tat protein," <i>J. Virol.</i> , 63:1181-1187, 1989.
	C19	Hingorani, "Polymorphisms in endothelial nitric oxide synthase and atherogenesis," <i>Atherosclerosis</i> , 154:52 1-527, 2000.
	C20	Jain <i>et al.</i> , "Enalapril acts through release of nitric oxide in patients with essential hypertension," <i>Renal Failure</i> , 23(5):651-657, 2001.
	C21	Jin <i>et al.</i> , "Transduction of human catalase mediated by an HIV-1 TAT protein basic domain and arginine-rich peptides into mammalian cells," <i>Free Rad. Biol. Med.</i> , 31(11):1509-1519, 2001.

25413943.1

EXAMINER: 

DATE CONSIDERED:

3/28/07

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UVMO:024US	Serial No. 10/808,248
<b>List of Patents and Publications for Applicant's</b>  <b>INFORMATION DISCLOSURE STATEMENT</b>  (Use several sheets if necessary)		Applicant Elmer M. Price <i>et al.</i>	
		Filing Date: March 24, 2004	Group: 1614
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C22	Kwon <i>et al.</i> , "Transduction of Cu,Zn-superoxide dismutase mediated by an HIV-1 Tat protein basic domain into mammalian cells," <i>FEBS Letters</i> , 485:163-167, 2000.
	C23	Leber <i>et al.</i> , "Characterization of recombinant human endothelial nitric-oxide synthase purified from the yeast <i>Pichia pastoris</i> ," <i>J. Biol. Chem.</i> , 274:37658-37664, 1999.
	C24	Lin <i>et al.</i> , "Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery," <i>Hypertension</i> , 30(3pt1):307-313, 1997.
	C25	Lopez Farre and Casado, "Heart failure, redox alterations, and endothelial dysfunction," <i>Hypertension</i> , 38:1400-1405, 2001.
	C26	Luscher, "Vascular protection: current possibilities and future perspectives," <i>IJCP Supplement</i> , 117:3-6, 2001.
	C27	Maeso <i>et al.</i> , "Effect of atorvastatin on endothelium-dependent constrictor factors in dyslipidemic rabbits," <i>General Pharmacol.</i> , 34(4):263-272, 2000.
	C28	Monacada <i>et al.</i> , "The L-arginine-nitric oxide pa," <i>New Engl. J. Med.</i> , 329:2002-2012, 1993.
	C29	Nagahara <i>et al.</i> , "Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration," <i>Nature Medicine</i> , 4:1449-1452, 1998.
	C30	Olsen <i>et al.</i> , "Endothelial dysfunction in resistance arteries is related to high blood pressure and circulating low density lipoproteins in previously treated hypertension," <i>Amer. J. Hypertension</i> , 14(9pt1):861-867, 2001.
	C31	Qian <i>et al.</i> , "Nitric oxide synthase gene therapy rapidly reduces adhesion molecule expression and inflammatory cell infiltration in carotid arteries of cholesterol-fed rabbits," <i>Circulation</i> , 99:2979-2982, 1999.
	C32	Ruben <i>et al.</i> , "Structural and functional characterization of human immunodeficiency virus tat protein," <i>J. Virology</i> , 63:1-8, 1989.
	C33	Sadaie <i>et al.</i> , "Human immunodeficiency virus type 1 rev protein as a negative trans-regulator," <i>DNA</i> , 8(9):669-674, 1989.
	C34	Schwarze <i>et al.</i> , "In vivo protein transduction: delivery of a biologically active protein into the mouse," <i>Science</i> , 285:1569-1572, 1999.
	C35	Schwarze <i>et al.</i> , "In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA," <i>Trends in Pharmacol. Science</i> , 21:45-48, 2000.

25413943.1

EXAMINER:

*Merch*

DATE CONSIDERED:

*3/29/07*



EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UVMO:024US	Serial No. 10/808,248
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Elmer M. Price <i>et al.</i>	
		Filing Date: March 24, 2004	Group: 1614
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C36	Suwaidei <i>et al.</i> , "Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction," <i>Circulation</i> , 101:948-954, 2000.
	C37	Teupe <i>et al.</i> , "Vascular gene transfer of phosphomimetic endothelial nitric oxide synthase (S1177D) using ultrasound-enhanced destruction of plasmid-loaded microbubbles improves vasoreactivity," <i>Circulation</i> , 105:1104-1109, 2002.
	C38	Torchilin <i>et al.</i> , "TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors," <i>Proc. Natl. Acad. Sci., USA</i> , 98:8786-8791, 2001.
	C39	Vallance <i>et al.</i> , "Nitric oxide--from mediator to medicines," <i>J. Royl. Coll. Physician London</i> , 28:209-219, 1994.
	C40	Venema <i>et al.</i> , "Role of the enzyme calmodulin-binding domain in membrane association and phospholipid inhibition of endothelial nitric oxide synthase," <i>Amer. Soc. Biochem. Molec. Biol.</i> , 270:14705-14711, 1995.
	C41	Woodman <i>et al.</i> , "Induction of nitric oxide synthase mRNA in coronary resistance arteries isolated from exercise-trained pigs," <i>Am. J. Physiol.</i> , 273(6pt2):H2575-2579, 1997.
	C42	Yang <i>et al.</i> , "Apolipoprotein B mRNA editing and the reduction in synthesis and secretion of the atherogenic risk factor, apolipoprotein B100 can be effectively targeted through TAT-mediated protein transduction," <i>Molec. Pharmacol.</i> , 61(2):269-276, 2002.
	C43	Yap <i>et al.</i> , "Distribution and function of recombinant endothelial nitric oxide synthase in transplanted hearts," <i>Cardiovascular Res.</i> , 42(3):720-727, 1999.

25413943.1

EXAMINER: DATE CONSIDERED: 

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.